Pharmafile Logo
Pharmafocus logo
Advanced Search

Xarelto

Showing 15 posts of 74 posts found.

Petition launched to raise AF and stroke awareness

April 20, 2012
Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke

Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …

News
Xarelto picture

NICE wants more information on Xarelto

March 13, 2012
Sales and Marketing Bayer, DVT, NICE, Xarelto

NICE is asking Bayer for more information about its blood thinner Xarelto in new guidance.  The watchdog is currently minded …

News

NICE set to reject Xarelto in AF

January 10, 2012
Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation

NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …

News

Xarelto succeeds in new study

November 14, 2011
Sales and Marketing Bayer, FDA, J&J, JJ, Xarelto

In a new study J&J and Bayer’s blood thinner Xarelto reduced deaths in patients after a heart attack, which could …

News

Emerging markets help Bayer through tough quarter

October 28, 2011
Sales and Marketing Bayer, Xarelto, emerging markets

Bayer has posted modest results for the third quarter, with growth in emerging markets compensating for austerity measures in Europe …

News

Astellas abandons oral anticoagulant darexaban

September 30, 2011
Research and Development Astellas, Eliquis, Xarelto, darexaban

Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …

News

Xarelto poised for two new chronic indications

September 26, 2011
Sales and Marketing Xarelto

Bayer HealthCare’s oral bloodthinner Xarelto has been recommended for approval in Europe for two new chronic indications. The Committee for …

News

Eliquis launched in the UK

September 19, 2011
Sales and Marketing Eliquis, Pradaxa, VTE, Xarelto

Eliquis, the latest entrant to the competitive oral anticoagulant market, has been launched in the UK.Co-developed and co-marketed by Pfizer …

News

FDA recommends Xarelto for new approval

September 12, 2011
Sales and Marketing Xarelto, atrial fibrillation, stroke

FDA advisors have recommended Bayer and Johnson & Johnson’s Xarelto be approved in the US for the prevention of stroke …

News
Boehringer Ingelheim

Pradaxa and Eliquis gain trial boost over warfarin

August 31, 2011
Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban

A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …

News

Xarelto receives FDA approval

July 4, 2011
Sales and Marketing Bayer, Eliquis, Johnson & Johnson, Pradaxa, Xarelto, anticoagulant

Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep …

News

NICE to appraise hep C drugs Victrelis and telaprevir

May 26, 2011
Sales and Marketing Brinavess, Ilaris, NICE, Victrelis, Xarelto, Zytiga, telaprevir

NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …

News

Merck drops oral anticoagulant

March 25, 2011
Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar

Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …

News
Bayer's Marijn Dekkers

Bayer goes for pharma growth

March 1, 2011
Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto

While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …

Feature

Key drug launches for 2011

January 20, 2011
Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir

This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …

Feature
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025